| Previous Close | 87.87 |
| Open | 88.17 |
| Bid | 71.12 x 1000 |
| Ask | 71.74 x 44000 |
| Day's Range | 87.95 - 89.06 |
| 52 Week Range | 66.72 - 92.97 |
| Volume | 1,857,317 |
| Avg. Volume | 2,427,553 |
| Market Cap | 108.44B |
| Beta | 0.73 |
| PE Ratio (TTM) | 12.27 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 3.30 (3.36%) |
| Ex-Dividend Date | 2017-05-16 |
| 1y Target Est | N/A |
- Bloomberg•6 hours ago
Domino Effect: Nestle Sale of L'Oreal Could Trigger Sanofi Move
Activist investor Dan Loeb’s pressure on Nestle SA to sell its stake in L’Oreal SA could lead to the unwinding of another long-standing investment: L’Oreal’s 10.4 billion-euro ($11.6 billion) holding in ...
GuruFocus.com•3 days agoGood Companies From Warren Buffett's Portfolio
Strong profit margins lead to investing opportunities
- Reuters•3 days ago
Portola shares soar after FDA approves clot preventing drug
The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery. The news sent Portola's shares up as much as 51 percent to $57.90. The drug, BevyxXa, known also as betrixaban, is the first oral treatment and first extended duration treatment for this patient population, the company said.